AUS
NZ
UK
CA
USA
IND
Highlights
- Dr Dimitris Voliotis has been appointed as the Chief Medical Officer of RAD.
- Dr Voliotis has designed and executed numerous registrational trials across various oncology indications.
- His industry experience spans global drug development from major pharma to start-ups.
Radiopharm Theranostics Limited (ASX:RAD) has appointed Dr Dimitris Voliotis as its Chief Medical Officer (CMO). With nearly 20 years of experience in biotechnology and pharmaceuticals across Europe and the US, Dr Voliotis brings a strong focus on the radiopharmaceutical sector and 12 years of academic research in preclinical and clinical studies.
Dr Voliotis' Extensive Experience
Dr Voliotis has significant industry experience in global drug development, having worked with large, medium-sized, and start-up pharmaceutical companies. He has designed and executed multiple registrational trials across various oncology indications, including numerous investigational new drug (IND) applications and clinical trials from preclinical stages through to Phase 1-4. His work has resulted in the approval of four drugs across eight different oncology indications.
Most recently, Dr Voliotis was Senior Vice President and Head of Clinical Development at Convergent Therapeutics, a radiopharmaceutical company. Previously, he held a similar role at Zentalis Pharmaceuticals (NASDAQ:ZNTL), an oncology firm. His career also includes nearly 13 years in development roles at Germany-based pharmaceutical firm Bayer AG and Japanese firm Eisai Inc.
In addition to his corporate experience, he has provided consultancy in oncology drug development with Magnesia Partners Consulting LLC, offering expert advice on clinical development and regulatory strategy.
Dr Voliotis earned his medical degree from the University of Cologne Medical School, where he also completed a doctoral thesis in cellular biology. He is board-certified in Internal Medicine, Medical Oncology, and Hematology.
RAD shares were trading at AU$0.034 apiece at the time of writing on 21 August 2024.
